Warts clinical trials

Explore recruiting warts clinical trials.

Recruiting warts studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Warts trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

VAC-WARTS Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LVERU®JUNIOR and 2LVERU® on the treatment of warts.

Belgium

Phase III and phase IV (Integrated) EU CTIS Study details

CONDYVAC. Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension

Spain, France, Italy, Netherlands, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women.

Norway, Sweden, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Warts trials by city

Warts in Toronto Warts in Vancouver Warts in Montreal Warts in Calgary Warts in Edmonton Warts in Ottawa Warts in Winnipeg Warts in Quebec City Warts in Hamilton Warts in Kitchener Warts in London Warts in Halifax Warts in New York Warts in Los Angeles Warts in Chicago Warts in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease